WHO Sounds Warning Over Acute Scarcity of Obesity Injections
Less than a tenth of individuals who could benefit from weight-loss injections such as Wegovy are able to get them, warns the WHO as it publishes its initial guidance on the medications.
Given more than one billion people worldwide currently obese, it is urging more widespread and fairer access to this class of drugs.
Per estimates, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.
"Our latest guidance affirms that excess weight is a chronic disease that can be managed with holistic and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are significant obstacles to broad access to the jabs that can aid individuals in losing substantial weight, says the body.
Weight-Loss Drug Supply Crisis
Despite the present most optimistic scenario, the manufacturing of GLP-1 therapies might only reach about 100 million people – under 10% of those who need them, per the WHO.
The advice urges countries and companies to expand access, by measures including voluntary licensing.
The intellectual property rights on a key compound – the core ingredient of a leading brand – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Jabs Operate
GLP-1 drugs replicate a biological compound to reduce digestion speed, reduce hunger and increase the sense of being full so people reduce food intake.
People typically begin shedding pounds in the initial weeks of beginning the weekly injections.
Evidence indicates users may regain a significant portion after a year of halting the drug, because their usual hunger come back.
To be carrying excess weight elevates your chance for experiencing medical conditions, like type 2 diabetes, heart disease, stroke, and some cancers.
Excess weight concerns individuals in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, per the health agency.